466 related articles for article (PubMed ID: 10537338)
21. Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study.
Meloni G; Foà R; Tosti S; Vignetti M; Mancini F; Guarini A; Marchis D; Gavosto F; Mandelli F
Leukemia; 1992 Aug; 6(8):780-5. PubMed ID: 1640729
[TBL] [Abstract][Full Text] [Related]
22. Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial.
Raza A; Jurcic JG; Roboz GJ; Maris M; Stephenson JJ; Wood BL; Feldman EJ; Galili N; Grove LE; Drachman JG; Sievers EL
Leuk Lymphoma; 2009 Aug; 50(8):1336-44. PubMed ID: 19557623
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.
Brethon B; Auvrignon A; Galambrun C; Yakouben K; Leblanc T; Bertrand Y; Leverger G; Baruchel A
BMC Cancer; 2006 Jun; 6():172. PubMed ID: 16805911
[TBL] [Abstract][Full Text] [Related]
24. Upfront use of gemtuzumab ozogamicin in young children with CD33-positive AML.
Sayar D; Burstein Y; Bielorai B; Toren A; Dvir R
Pediatr Blood Cancer; 2010 Jul; 55(1):183-5. PubMed ID: 20310000
[TBL] [Abstract][Full Text] [Related]
25. [Immunophenotype characteristics and prognosis of acute leukemia patients with cross expressing lymphoid and myeloid lineage associated antigens].
Jiang NG; Chen XM; Zhu HL; Zhong L; Zeng TT; Jia YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1405-9. PubMed ID: 21176339
[TBL] [Abstract][Full Text] [Related]
26. Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemia.
Caron PC; Scheinberg DA
Leuk Lymphoma; 1993; 11 Suppl 2():1-6. PubMed ID: 8124221
[TBL] [Abstract][Full Text] [Related]
27. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia.
Robertson MJ; Soiffer RJ; Freedman AS; Rabinowe SL; Anderson KC; Ervin TJ; Murray C; Dear K; Griffin JD; Nadler LM
Blood; 1992 May; 79(9):2229-36. PubMed ID: 1571539
[TBL] [Abstract][Full Text] [Related]
28. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia.
Lapusan S; Vidriales MB; Thomas X; de Botton S; Vekhoff A; Tang R; Dumontet C; Morariu-Zamfir R; Lambert JM; Ozoux ML; Poncelet P; San Miguel JF; Legrand O; DeAngelo DJ; Giles FJ; Marie JP
Invest New Drugs; 2012 Jun; 30(3):1121-31. PubMed ID: 21519855
[TBL] [Abstract][Full Text] [Related]
29. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias.
McGraw KJ; Rosenblum MG; Cheung L; Scheinberg DA
Cancer Immunol Immunother; 1994 Dec; 39(6):367-74. PubMed ID: 8001024
[TBL] [Abstract][Full Text] [Related]
30. Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: a report from the Children's Cancer Group.
Sievers EL; Lange BJ; Sondel PM; Krailo MD; Gan J; Liu-Mares W; Feig SA
J Clin Oncol; 1998 Mar; 16(3):914-9. PubMed ID: 9508173
[TBL] [Abstract][Full Text] [Related]
31. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
Cortes J; Tsimberidou AM; Alvarez R; Thomas D; Beran M; Kantarjian H; Estey E; Giles FJ
Cancer Chemother Pharmacol; 2002 Dec; 50(6):497-500. PubMed ID: 12451477
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
Sievers EL; Larson RA; Stadtmauer EA; Estey E; Löwenberg B; Dombret H; Karanes C; Theobald M; Bennett JM; Sherman ML; Berger MS; Eten CB; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR;
J Clin Oncol; 2001 Jul; 19(13):3244-54. PubMed ID: 11432892
[TBL] [Abstract][Full Text] [Related]
33. Antibody-targeted therapy for myeloid leukemia.
Appelbaum FR
Semin Hematol; 1999 Oct; 36(4 Suppl 6):2-8. PubMed ID: 10530710
[TBL] [Abstract][Full Text] [Related]
34. Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.
Kersemans V; Cornelissen B; Minden MD; Brandwein J; Reilly RM
J Nucl Med; 2008 Sep; 49(9):1546-54. PubMed ID: 18703602
[TBL] [Abstract][Full Text] [Related]
35. Engraftment of leukocyte subsets following autologous bone marrow transplantation in acute myeloid leukemia using anti-myeloid (CD14 and CD15) monoclonal antibody-purged bone marrow.
Ericson SG; Colby E; Welch L; Ball ED
Bone Marrow Transplant; 1992 Feb; 9(2):129-37. PubMed ID: 1373982
[TBL] [Abstract][Full Text] [Related]
36. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Farag SS; George SL; Lee EJ; Baer M; Dodge RK; Becknell B; Fehniger TA; Silverman LR; Crawford J; Bloomfield CD; Larson RA; Schiffer CA; Caligiuri MA
Clin Cancer Res; 2002 Sep; 8(9):2812-9. PubMed ID: 12231521
[TBL] [Abstract][Full Text] [Related]
37. A phase I study of recombinant human soluble interleukin-1 receptor (rhu IL-1R) in patients with relapsed and refractory acute myeloid leukemia.
Bernstein SH; Fay J; Frankel S; Christiansen N; Baer MR; Jacobs C; Blosch C; Hanna R; Herzig G
Cancer Chemother Pharmacol; 1999; 43(2):141-4. PubMed ID: 9923819
[TBL] [Abstract][Full Text] [Related]
38. Generation of cytotoxic NK cells in peripheral blood and bone marrow of patients with acute myelogenous leukemia after continuous infusion with recombinant interleukin-2.
Lotzová E; Savary CA; Schachner JR; Huh JO; McCredie K
Am J Hematol; 1991 Jun; 37(2):88-99. PubMed ID: 2069169
[TBL] [Abstract][Full Text] [Related]
39. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
Caligiuri MA; Murray C; Robertson MJ; Wang E; Cochran K; Cameron C; Schow P; Ross ME; Klumpp TR; Soiffer RJ
J Clin Invest; 1993 Jan; 91(1):123-32. PubMed ID: 7678599
[TBL] [Abstract][Full Text] [Related]
40. Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.
Soiffer RJ; Chapman PB; Murray C; Williams L; Unger P; Collins H; Houghton AN; Ritz J
Clin Cancer Res; 1997 Jan; 3(1):17-24. PubMed ID: 9815532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
